GLP-1 Drugs and Gastroparesis: What Patients Should Know About Ozempic, Wegovy, Rybelsus, and Mounjaro

GLP-1 medications have become some of the most widely discussed prescription drugs in the United States. Originally developed to help people manage type 2 diabetes, these medications are now also commonly prescribed for weight loss and metabolic health.

Drugs such as Ozempic, Wegovy, Rybelsus, and Mounjaro all work by influencing hormones that regulate blood sugar, appetite, and digestion. For many patients, these medications have helped improve glucose control and support weight loss. However, as their use has expanded, concerns have also grown about potential gastrointestinal side effects, including a condition called gastroparesis, sometimes referred to as stomach paralysis.

For patients who have experienced severe digestive symptoms after taking a GLP-1 medication, understanding the connection between these drugs and gastroparesis is an important step in determining what to do next.

Understanding How GLP-1 Drugs Work

GLP-1 drugs mimic or enhance the activity of a natural hormone called glucagon-like peptide-1 (GLP-1). This hormone helps regulate blood sugar and appetite by:

• Stimulating insulin release
• Suppressing glucagon production
• Slowing digestion and stomach emptying
• Promoting feelings of fullness

These effects can be beneficial for patients managing diabetes or obesity. But the same mechanism that slows digestion can also lead to gastrointestinal complications in some individuals.

Several medications fall into this category:

• Ozempic is an injectable GLP-1 receptor agonist prescribed for type 2 diabetes.
• Wegovy is a higher dose injectable GLP-1 medication approved for weight management.
• Rybelsus is an oral tablet form of semaglutide used for diabetes treatment.
• Mounjaro activates both GLP-1 and GIP receptors, meaning it acts as a dual GIP/GLP-1 receptor agonist.

Although these medications differ slightly in formulation and dosing, they share a key physiological effect: they slow the movement of food through the stomach.

For some patients, this effect may contribute to a serious digestive disorder known as gastroparesis.

What Is Gastroparesis?

Gastroparesis is a condition in which the stomach cannot empty food normally. Instead of moving food through the digestive tract at a regular pace, the stomach muscles work too slowly or not effectively at all.

This delayed emptying can cause symptoms such as:

• Persistent nausea
• Vomiting that may occur hours after eating
• Severe bloating
• Early fullness when eating
• Abdominal pain
• Malnutrition or unintended weight loss

In severe cases, food may remain in the stomach for long periods, creating significant digestive complications and affecting a person’s overall health and quality of life.

Because GLP-1 medications intentionally slow gastric emptying, some patients have reported prolonged or severe digestive symptoms after taking these drugs.

How GLP-1 Medications May Be Linked to Gastroparesis

All four of the medications discussed here—Ozempic, Wegovy, Rybelsus, and Mounjaro—influence gastric emptying as part of their intended mechanism.

For most patients, this slowing of digestion is mild and temporary. It helps regulate appetite and blood sugar levels. However, in some individuals, the effect may become more pronounced and lead to persistent gastrointestinal symptoms.

Mounjaro’s mechanism may be particularly relevant to this discussion. Because it acts on two hormone pathways (GIP and GLP-1 receptors) rather than one, it can have strong effects on metabolic signaling and digestion. Some patients taking the medication have reported severe nausea, vomiting, or symptoms consistent with delayed gastric emptying.

While research continues into the exact relationship between these medications and gastroparesis, the possibility of significant digestive complications has become an important area of concern for patients, physicians, and regulators.

Diagnosing Gastroparesis: The Gastric Emptying Study

When doctors suspect gastroparesis, the most widely accepted diagnostic test is the gastric emptying study.

According to the Cleveland Clinic, this test measures how quickly food moves from the stomach into the small intestine. During the procedure, a patient eats a small meal containing a safe trace amount of radioactive material. Imaging equipment then tracks how quickly the meal leaves the stomach.

If the stomach empties too slowly, doctors may diagnose gastroparesis.

This test is considered the gold standard for confirming delayed gastric emptying and helps doctors distinguish gastroparesis from other gastrointestinal disorders that may cause similar symptoms.

For patients experiencing persistent nausea, vomiting, or severe digestive problems while taking a GLP-1 medication, a gastric emptying study may be an important step in determining the cause.

When Digestive Symptoms Become Serious

Many medications cause mild gastrointestinal side effects when treatment begins. However, persistent or worsening symptoms may signal something more serious.

Patients who have taken GLP-1 medications sometimes report symptoms such as:

• Ongoing nausea that does not improve
• Frequent vomiting
• Inability to tolerate normal meals
• Severe bloating or stomach pain
• Significant weight loss due to digestive issues

If symptoms like these develop and continue after starting medications such as Ozempic, Wegovy, Rybelsus, or Mounjaro, it may be important to speak with a medical professional about further evaluation.

In some cases, patients later learn that their symptoms are related to gastroparesis or delayed gastric emptying.

The Hidden Cost of the “Weight Loss Revolution”

While GLP-1 drugs like Mounjaro and Ozempic have been hailed as medical breakthroughs, thousands of patients are now reporting that the price of weight loss was much higher than they were led to believe. Many users have transitioned from common side effects like mild nausea to life-altering conditions such as gastroparesis (stomach paralysis), intestinal blockages, and even sudden vision loss (NAION).

These aren’t just “stomach aches”—they are severe medical events that have left people unable to eat regular meals, forced them into emergency surgeries, or caused permanent disability. If you have been hospitalized for persistent vomiting or diagnosed with a paralyzed digestive tract after starting these medications, it is important to know that these complications may not be a “normal” part of the treatment, but rather a result of insufficient safety warnings from the manufacturers.

Why You May Be Entitled to Compensation

The core of the current national litigation is the “failure to warn.” Lawsuits allege that pharmaceutical companies prioritized record-breaking profits over patient safety by downplaying the risk of permanent organ damage and severe gastrointestinal failure. If you have suffered a qualifying injury, you may be entitled to compensation for your medical bills, lost wages, and the physical pain you’ve endured. Pursuing a claim is not just about a potential settlement; it’s about holding these companies accountable for providing the full truth to patients and doctors alike. 

If your life has been reshaped by these medications, now is the time to gather your medical records and consult with a legal professional to see if you qualify for the ongoing multidistrict litigation.

Understanding Your Legal Options

When a medication leads to serious or unexpected complications, patients often have questions about whether they were adequately warned about the risks.

Pharmaceutical litigation frequently focuses on whether drug manufacturers properly disclosed potential side effects and whether patients and doctors had the information needed to make informed treatment decisions.

If a patient develops gastroparesis or other severe digestive complications after using a GLP-1 medication, it may be helpful to discuss the situation with an attorney experienced in pharmaceutical injury cases.

Legal guidance can help determine whether the circumstances surrounding a patient’s injury may warrant further investigation.

Speak With Clark Perdue About Your Case

If you or a loved one experienced severe gastrointestinal symptoms or were diagnosed with gastroparesis after taking Ozempic, Wegovy, Rybelsus, or Mounjaro, you may have questions about what steps to take next.

Clark, Perdue & List represents individuals harmed by dangerous drugs and pharmaceutical negligence. Our office can review your situation, help you understand your legal options, and determine whether you may have a claim related to GLP-1 medications.

To learn more or schedule a consultation, contact our office today. An experienced pharmaceutical litigation attorney on our team can help you evaluate your case and protect your rights.